

S Ananth Karumanchi

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/3487816/publications.pdf](https://exaly.com/author-pdf/3487816/publications.pdf)

Version: 2025-02-01

277

PR articles

33,808

PR citations

3816

84

PR h-index

3557

178

g-index

311

documents

38390

doc citations

4016

90

h-index

35519

citing authors

#	ARTICLE	IF	CITATIONS
1	Total and Free Placental Growth Factor Levels During Preeclampsia and Fetal Growth Restriction. Hypertension, 2025, 82, 883-893.	6.6	4
2	Strikingly High Activity of 15â€Lipoxygenase Towards Diâ€Polyunsaturated Arachidonoyl/Adrenoylâ€Phosphatidylethanolamines Generates Peroxidation Signals of Ferroptotic Cell Death. Angewandte Chemie, 2024, 136, .	1.4	0
3	Strikingly High Activity of 15â€Lipoxygenase Towards Diâ€Polyunsaturated Arachidonoyl/Adrenoylâ€Phosphatidylethanolamines Generates Peroxidation Signals of Ferroptotic Cell Death. Angewandte Chemie - International Edition, 2024, 63, .	14.4	39
4	Translation of mechanistic advances in preeclampsia to the clinic: Long and winding road. FASEB Journal, 2024, 38, .	0.6	14
5	SOX9 switch links regeneration to fibrosis at the single-cell level in mammalian kidneys. Science, 2024, 383, .	36.2	102
6	Prior Exposure to Experimental Preeclampsia Increases Atherosclerotic Plaque Inflammation in Atherogenic Miceâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 946-953.	6.0	9
7	Placental IGFBP1 levels during early pregnancy and the risk of insulin resistance and gestational diabetes. Nature Medicine, 2024, 30, 1689-1695.	33.0	35
8	Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human. Science Translational Medicine, 2024, 16, .	12.5	22
9	Data-driven prediction of continuous renal replacement therapy survival. Nature Communications, 2024, 15, .	13.7	7
10	Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. American Journal of Obstetrics and Gynecology, 2024, 231, 363.e1-363.e11.	2.4	16
11	Two decades of advances in preeclampsia research: molecular mechanisms and translational studies. Journal of Clinical Investigation, 2024, 134, .	10.6	12
12	Perinatal mood and anxiety disorders: biomarker discovery using plasma proteomics. American Journal of Obstetrics and Gynecology, 2023, 229, 166.e1-166.e16.	2.4	20
13	Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia. Circulation Research, 2023, 132, 674-689.	13.2	29
14	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension, 2022, 27, 148-169.	1.5	763
15	Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertension, 2022, 27, 42-50.	1.5	175
16	Risk-Factor Based Lead Screening and Correlation with Blood Lead Levels in Pregnancy. Maternal and Child Health Journal, 2022, 26, 185-192.	1.4	4
17	Cardiovascular and hemodynamic consequences of recombinant placental growth factor administration in Guinea pigs. Hypertension in Pregnancy, 2022, 41, 99-106.	1.2	2
18	Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series. American Journal of Reproductive Immunology, 2022, 88, .	2.1	11

#	ARTICLE	IF	CITATIONS
19	Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 135-149.	5.5	47
20	Animal Models of Cardiovascular Complications of Pregnancy. <i>Circulation Research</i> , 2022, 130, 1763-1779.	13.2	15
21	Impaired renal reserve contributes to preeclampsia via the kynurenine and soluble fms-like tyrosine kinase 1 pathway. <i>Journal of Clinical Investigation</i> , 2022, 132, .	10.6	21
22	Cell-Free RNA Transcriptome and Prediction of Adverse Pregnancy Outcomes. <i>Clinical Chemistry</i> , 2022, 68, 1358-1360.	1.1	4
23	Risk of pre-eclampsia in patients with a maternal genetic predisposition to common medical conditions: a case-control study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 55-65.	3.1	29
24	Low Prenatal Vitamin D Metabolite Ratio and Subsequent Postpartum Depression Risk. <i>Journal of Women's Health</i> , 2021, 30, 113-120.	2.1	13
25	Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy. <i>Human Immunology</i> , 2021, 82, 362-370.	1.0	63
26	Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease. <i>Pregnancy Hypertension</i> , 2021, 24, 58-64.	1.5	22
27	Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay. <i>PLoS ONE</i> , 2021, 16, e0254158.	2.3	7
28	An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo. <i>Science Translational Medicine</i> , 2021, 13, .	12.5	34
29	Normalization of wall shear stress as a physiological mechanism for regulating maternal uterine artery expansive remodeling during pregnancy. <i>FASEB BioAdvances</i> , 2021, 3, 702-708.	1.8	6
30	IL-6 Inhibition Reduces Neuronal Injury in a Murine Model of Ventilator-induced Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 403-412.	3.8	35
31	Interleukin-6 mediates delirium-like phenotypes in a murine model of urinary tract infection. <i>Journal of Neuroinflammation</i> , 2021, 18, .	9.0	37
32	Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia. <i>Hypertension</i> , 2020, 76, 875-883.	6.6	37
33	Standardising definitions for the pre-eclampsia core outcome set: A consensus development study. <i>Pregnancy Hypertension</i> , 2020, 21, 208-217.	1.5	18
34	A mouse model of placenta accreta spectrum. <i>Placenta</i> , 2020, 99, 8-15.	1.1	14
35	Sexually Dimorphic Crosstalk at the Maternal-Fetal Interface. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4831-e4847.	4.1	70
36	Lead exposure and association with angiogenic factors and hypertensive disorders of pregnancy. <i>Pregnancy Hypertension</i> , 2020, 22, 93-98.	1.5	11

#	ARTICLE	IF	CITATIONS
37	Immune cell infiltrate at the utero-placental interface is altered in placenta accreta spectrum disorders. Archives of Gynecology and Obstetrics, 2020, 301, 499-507.	1.9	22
38	Placenta accreta spectrum: biomarker discovery using plasma proteomics. American Journal of Obstetrics and Gynecology, 2020, 223, 433.e1-433.e14.	2.4	61
39	Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	10.1	34
40	A Step-Wedge in the Biochemical Diagnosis of Preeclampsia. Clinical Chemistry, 2019, 65, 1348-1349.	1.1	0
41	Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertension in Pregnancy, 2019, 38, 193-199.	1.2	47
42	Risk of ischemic placental disease is increased following in vitro fertilization with oocyte donation: a retrospective cohort study. Journal of Assisted Reproduction and Genetics, 2019, 36, 1917-1926.	2.3	24
43	Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD. Kidney International Reports, 2019, 4, 1735-1741.	2.5	6
44	Research Recommendations From the National Institutes of Health Workshop on Predicting, Preventing, and Treating Preeclampsia. Hypertension, 2019, 73, 757-766.	6.6	44
45	Vitamin D Binding Protein Deficiency and Homozygous Deletion of the <i>GC</i> Gene. New England Journal of Medicine, 2019, 380, 2582-2587.	34.6	5
46	Solving Baroreceptor Mystery: Role of PIEZO Ion Channels. Journal of the American Society of Nephrology: JASN, 2019, 30, 911-913.	0.4	19
47	Preeclampsia. Circulation Research, 2019, 124, 1094-1112.	13.2	1,723
48	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019, 15, 275-289.	32.8	964
49	AP39, a Modulator of Mitochondrial Bioenergetics, Reduces Antiangiogenic Response and Oxidative Stress in Hypoxia-Exposed Trophoblasts. American Journal of Pathology, 2019, 189, 104-114.	3.4	67
50	Smooth Muscle Cell Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging. Hypertension, 2018, 71, 609-621.	6.6	74
51	Metabolic and Hypertensive Complications of Pregnancy in Women with Nephrolithiasis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 612-619.	4.2	22
52	Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Research, 2018, 46, 2185-2196.	15.5	172
53	Hepatic dysfunction and thrombocytopenia induced by excess sFlt1 in mice lacking endothelial nitric oxide synthase. Scientific Reports, 2018, 8, .	3.4	26
54	Inadequate safety reporting in pre-eclampsia trials: a systematic evaluation. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 795-803.	3.1	22

#	ARTICLE	IF	CITATIONS
55	Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis. <i>Obstetrics and Gynecology</i> , 2018, 131, 63-69.	1.9	17
56	RNAi modulation of placental sFLT1 for the treatment of preeclampsia. <i>Nature Biotechnology</i> , 2018, 36, 1164-1173.	29.8	168
57	Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease. <i>American Journal of Pathology</i> , 2018, 188, 2147-2154.	3.4	42
58	Updates on Screening, Prevention, Treatment, and Genetic Markers for Preeclampsia. <i>Clinical Chemistry</i> , 2018, 64, 1684-1689.	1.1	5
59	Cerebrospinal Fluid Protein Changes in Preeclampsia. <i>Hypertension</i> , 2018, 72, 219-226.	6.6	33
60	Angiogenic biomarkers in triage and risk for preeclampsia with severe features. <i>Pregnancy Hypertension</i> , 2018, 13, 100-106.	1.5	62
61	Gene-Centric Analysis of Preeclampsia Identifies Maternal Association at <i>PLEKHG1</i> . <i>Hypertension</i> , 2018, 72, 408-416.	6.6	55
62	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF β 1 Axis. <i>Clinical Cancer Research</i> , 2018, 24, 6078-6097.	6.8	51
63	Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2018, 72, 24-43.	6.6	1,714
64	Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. <i>Nature</i> , 2018, 565, 96-100.	37.9	201
65	Risk of Preeclampsia and Pregnancy Complications in Women With a History of Acute Kidney Injury. <i>Hypertension</i> , 2018, 72, 451-459.	6.6	48
66	Relationship between hypoxia and downstream pathogenic pathways in preeclampsia. <i>Hypertension in Pregnancy</i> , 2017, 36, 145-150.	1.2	51
67	High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on Hemodialysis. <i>Clinical Chemistry</i> , 2017, 63, 477-485.	1.1	50
68	Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes. <i>Science Signaling</i> , 2017, 10, .	5.4	79
69	Placental soluble fms-like tyrosine kinase expression in small for gestational age infants and risk for adverse outcomes. <i>Placenta</i> , 2017, 52, 10-16.	1.1	15
70	Pregnancy Outcomes after Clinical Recovery from AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1566-1574.	0.4	79
71	FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. <i>Scientific Reports</i> , 2017, 7, .	3.4	51
72	Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) and Risk of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. <i>World Neurosurgery</i> , 2017, 108, 84-89.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Identification of Novel Non-steroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects and devoid of Hypercalcemia. Scientific Reports, 2017, 7, .	3.4	13
74	Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Seminars in Nephrology, 2017, 37, 386-397.	2.3	205
75	Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation. Archives of Gynecology and Obstetrics, 2017, 296, 257-262.	1.9	26
76	Acute homeostatic changes following Vitamin D2 supplementation. Journal of the Endocrine Society, 2017, . .	0.3	6
77	The pathology of eclampsia: An autopsy series. Hypertension in Pregnancy, 2017, 36, 259-268.	1.2	44
78	Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. Journal of Clinical Investigation, 2016, 126, 2561-2574.	10.6	132
79	Reduction of carbamylated albumin by extended hemodialysis. Hemodialysis International, 2016, 20, 510-521.	1.1	10
80	KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertension in Pregnancy, 2016, 35, 330-345.	1.2	44
81	Angiogenic Factors in Preeclampsia. Hypertension, 2016, 67, 1072-1079.	6.6	144
82	Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension, 2016, 67, 1263-1272.	6.6	107
83	Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension, 2016, 67, 1273-1280.	6.6	77
84	A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertension, 2016, 6, 274-278.	1.5	50
85	Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. Digestive Diseases and Sciences, 2016, 61, 3609-3620.	2.1	9
86	Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertension, 2016, 6, 333-339.	1.5	9
87	Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1809-1816.	4.2	28
88	Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13450-13455.	7.5	69
89	A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes and Control, 2016, 27, 1009-1017.	1.7	4
90	Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertension, 2016, 6, 313-319.	1.5	52

#	ARTICLE	IF	CITATIONS
91	PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model. <i>Biology of Reproduction</i> , 2016, 95, 132-132.	2.5	41
92	National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness. <i>Hypertension</i> , 2016, 68, 281-288.	6.6	52
93	Revisiting decidual vasculopathy. <i>Placenta</i> , 2016, 42, 37-43.	1.1	60
94	Toward a Better Diagnosis for Preeclampsia. <i>Clinical Chemistry</i> , 2016, 62, 913-915.	1.1	14
95	Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 594.e1-594.e11.	2.4	22
96	ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 120-131.	0.4	15
97	PGC1 α drives NAD biosynthesis linking oxidative metabolism to renal protection. <i>Nature</i> , 2016, 531, 528-532.	37.9	501
98	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 518-536.	18.1	183
99	Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. <i>Hypertension</i> , 2016, 67, 740-747.	6.6	134
100	Sequential plasma angiogenic factors levels in women with suspected preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 89.e1-89.e10.	2.4	68
101	Preeclampsia and Pregnancy-Related Hypertensive Disorders. <i>Hypertension</i> , 2016, 67, 238-242.	6.6	84
102	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 903-913.	0.4	247
103	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 108.e1-108.e14.	2.4	145
104	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 498-507.	2.1	18
105	Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Patients with Obstructive Sleep Apnea. <i>PLoS ONE</i> , 2016, 11, e0154503.	2.3	5
106	Induced Human Decidual NK-Like Cells Improve Utero-Placental Perfusion in Mice. <i>PLoS ONE</i> , 2016, 11, e0164353.	2.3	21
107	Placental growth factor administration prevents hypertension, increased sFlt-1 levels and reduced glomerular filtration rate responses to placental ischemia. <i>FASEB Journal</i> , 2016, 30, .	0.6	0
108	Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. <i>PLoS ONE</i> , 2015, 10, e0126815.	2.3	54

#	ARTICLE	IF	CITATIONS
109	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. <i>Prenatal Diagnosis</i> , 2015, 35, 386-393.	2.3	32
110	Exposure to Experimental Preeclampsia in Mice Enhances the Vascular Response to Future Injury. <i>Hypertension</i> , 2015, 65, 863-870.	6.6	86
111	Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. <i>Kidney International</i> , 2015, 87, 1201-1208.	5.3	75
112	The Effects of Parenteral Amino Acid Therapy on Protein Carbamylation in Maintenance Hemodialysis Patients. , 2015, 25, 388-392.		30
113	Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia. <i>Hypertension</i> , 2015, 66, 117-125.	6.6	60
114	Interferon α and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. <i>Arthritis and Rheumatology</i> , 2015, 67, 977-987.	6.2	78
115	Preeclampsia: An Old Disease with New Tools for Better Diagnosis and Risk Management. <i>Clinical Chemistry</i> , 2015, 61, 694-698.	1.1	16
116	Endothelial dysfunction and metabolic syndrome in preeclampsia: an alternative viewpoint. <i>Journal of Reproductive Immunology</i> , 2015, 108, 42-47.	1.2	51
117	24,25-Dihydroxyvitamin D3 and Vitamin D Status of Community-Dwelling Black and White Americans. <i>Clinical Chemistry</i> , 2015, 61, 877-884.	1.1	102
118	Pathogenesis of preeclampsia. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 131-138.	2.2	221
119	Hydrogen sulfide. <i>Current Opinion in Nephrology and Hypertension</i> , 2015, 24, 170-176.	2.2	59
120	Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. <i>Circulation</i> , 2015, 132, 1726-1733.	18.1	170
121	Molecular Mechanisms of Preeclampsia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a023473.	6.6	157
122	Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination. <i>PLoS ONE</i> , 2014, 9, e85258.	2.3	32
123	Carbon Monoxide Prevents Hypertension and Proteinuria in an Adenovirus sFlt-1 Preeclampsia-Like Mouse Model. <i>PLoS ONE</i> , 2014, 9, e106502.	2.3	46
124	Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF 1α pathway. <i>FASEB Journal</i> , 2014, 28, 4324-4334.	0.6	48
125	Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". <i>Hypertension in Pregnancy</i> , 2014, 33, 525-525.	1.2	1
126	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. <i>Hypertension in Pregnancy</i> , 2014, 33, 427-439.	1.2	39

#	ARTICLE	IF	CITATIONS
127	Vitamin D-Binding Protein and Vitamin D in Blacks and Whites. <i>New England Journal of Medicine</i> , 2014, 370, 878-881.	34.6	90
128	Pre-eclampsia and cardiovascular disease. <i>Cardiovascular Research</i> , 2014, 101, 579-586.	5.5	182
129	Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. <i>Hypertension in Pregnancy</i> , 2014, 33, 250-259.	1.2	43
130	The Authors Reply. <i>American Journal of Epidemiology</i> , 2014, 180, 758-758.	3.3	0
131	Aldosterone Promotes Vascular Remodeling by Direct Effects on Smooth Muscle Cell Mineralocorticoid Receptors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 355-364.	6.0	115
132	The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. <i>Hypertension in Pregnancy</i> , 2014, 33, 81-92.	1.2	51
133	Welles et al. Respond to "Low Vitamin D and Cardiovascular Disease". <i>American Journal of Epidemiology</i> , 2014, 179, 1291-1292.	3.3	0
134	Protein Carbamylation in Kidney Disease: Pathogenesis and Clinical Implications. <i>American Journal of Kidney Diseases</i> , 2014, 64, 793-803.	1.4	116
135	Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 68.e1-68.e4.	2.4	59
136	Differential immunoregulation in successful oocyte donation pregnancies compared with naturally conceived pregnancies. <i>Journal of Reproductive Immunology</i> , 2014, 101-102, 96-103.	1.2	31
137	Hydrogen Sulfide Attenuates sFlt1-Induced Hypertension and Renal Damage by Upregulating Vascular Endothelial Growth Factor. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 717-725.	0.4	103
138	Vitamin D Deficiency and Cardiovascular Events in Patients With Coronary Heart Disease: Data From the Heart and Soul Study. <i>American Journal of Epidemiology</i> , 2014, 179, 1279-1287.	3.3	81
139	Vitamin D-Binding Protein and Vitamin D Status of Black Americans and White Americans. <i>New England Journal of Medicine</i> , 2013, 369, 1991-2000.	34.6	974
140	Hydrogen peroxide-responsive copolyoxalate nanoparticles for detection and therapy of ischemia-reperfusion injury. <i>Journal of Controlled Release</i> , 2013, 172, 1102-1110.	11.0	83
141	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 120-128.	1.1	63
142	Preeclampsia Is Associated With the Presence of Transcriptionally Active Placental Fragments in the Maternal Lung. <i>Hypertension</i> , 2013, 62, 608-613.	6.6	41
143	Moving Forward in Sepsis Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1264-1265.	8.9	0
144	Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure. <i>Science Translational Medicine</i> , 2013, 5, .	12.5	167

#	ARTICLE	IF	CITATIONS
145	Response to Are Aldosterone Levels Inappropriately Low in Preeclampsia?. Hypertension, 2013, 62, .	6.6	0
146	Vascular Endothelial Growth Factor-A and Aldosterone. Hypertension, 2013, 61, 1111-1117.	6.6	61
147	Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1927-1934.	4.2	39
148	Circulating Lymphangiogenic Factors in Preeclampsia. Hypertension in Pregnancy, 2013, 32, 42-49.	1.2	20
149	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertension in Pregnancy, 2013, 32, 189-201.	1.2	142
150	Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis. PLoS ONE, 2013, 8, e56389.	2.3	22
151	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1135-1141.	1.7	19
152	Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L36-L46.	3.2	136
153	Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. Hypertension, 2012, 59, 256-264.	6.6	165
154	Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1447-1452.	1.7	38
155	eNOS Deficiency Acts through Endothelin to Aggravate sFlt-1-Induced Pre-Eclampsia-Like Phenotype. Journal of the American Society of Nephrology: JASN, 2012, 23, 652-660.	0.4	101
156	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation, 2012, 125, 911-919.	18.1	607
157	Familial Factors in the Association between Preeclampsia and Later ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1819-1826.	4.2	37
158	Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney International, 2012, 82, 84-89.	5.3	184
159	Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure. Circulation, 2012, 125, 2728-2738.	18.1	107
160	The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clinical Chemistry, 2012, 58, 837-845.	1.1	120
161	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. Hypertension, 2012, 60, 451-458.	6.6	95
162	Cisplatin Nephrotoxicity Involves Mitochondrial Injury with Impaired Tubular Mitochondrial Enzyme Activity. Journal of Histochemistry and Cytochemistry, 2012, 60, 521-529.	1.5	112

#	ARTICLE	IF	CITATIONS
163	Preeclampsia and Retinopathy of Prematurity in Preterm Births. <i>Pediatrics</i> , 2012, 130, e101-e107.	4.5	52
164	Correlation of Cystatin-C with Glomerular Filtration Rate by Inulin Clearance in Pregnancy. <i>Hypertension in Pregnancy</i> , 2012, 31, 22-30.	1.2	27
165	Hemodynamic, Vascular, and Reproductive Impact of FMS-Like Tyrosine Kinase 1 (FLT1) Blockade on the Uteroplacental Circulation During Normal Mouse Pregnancy ¹ . <i>Biology of Reproduction</i> , 2012, 86, .	2.5	10
166	Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. <i>Critical Care Medicine</i> , 2012, 40, 3034-3041.	0.5	172
167	Relaxin' with endothelial progenitor cells. <i>Blood</i> , 2012, 119, 326-327.	4.2	0
168	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , 2012, 485, 333-338.	37.9	514
169	Angiogenic Factors in Preeclampsia and Related Disorders. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006585-a006585.	6.6	107
170	The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 759-776.	10.6	88
171	Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia. <i>PLoS ONE</i> , 2012, 7, e48259.	2.3	55
172	Preeclampsia, a Disease of the Maternal Endothelium. <i>Circulation</i> , 2011, 123, 2856-2869.	18.1	933
173	Angiogenic Factors and Preeclampsia. <i>Seminars in Nephrology</i> , 2011, 31, 33-46.	2.3	420
174	Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. <i>Nature Medicine</i> , 2011, 17, 952-960.	33.0	811
175	Circulating angiogenic and antiangiogenic factors in women with eclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 152.e1-152.e9.	2.4	94
176	Midpregnancy levels of angiogenic markers in relation to maternal characteristics. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 244.e1-244.e12.	2.4	36
177	Preeclampsia and the risk of large-for-gestational-age infants. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 425.e1-425.e6.	2.4	13
178	Placental expression of angiogenic factors in Trisomy 13. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 546.e1-546.e4.	2.4	18
179	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. <i>Cancer Causes and Control</i> , 2011, 22, 1587-1595.	1.7	20
180	Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1609-1616.	4.9	323

#	ARTICLE	IF	CITATIONS
181	Early Outcomes among Those Initiating Chronic Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2642-2649.	4.2	132
182	Angiogenic Factors in Maternal Circulation and the Risk of Severe Fetal Growth Restriction. <i>American Journal of Epidemiology</i> , 2011, 173, 630-639.	3.3	83
183	WT1-Dependent Sulfatase Expression Maintains the Normal Glomerular Filtration Barrier. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1286-1296.	0.4	65
184	Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. <i>Circulation</i> , 2011, 124, 940-950.	18.1	333
185	Adipose Tissue-Derived Soluble Fms-Like Tyrosine Kinase 1 Is an Obesity-Relevant Endogenous Paracrine Adipokine. <i>Hypertension</i> , 2011, 58, 37-42.	6.6	27
186	Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. <i>Journal of Cell Science</i> , 2011, 124, 2132-2142.	2.4	14
187	Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. <i>Cardiovascular Research</i> , 2011, 91, 632-639.	5.5	63
188	Pre-Eclampsia, Soluble Fms-Like Tyrosine Kinase 1, and the Risk of Reduced Thyroid Function: Nested Case-Control and Population Based Study. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 213-214.	0.5	0
189	Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 40.e1-40.e7.	2.4	115
190	Angiogenic dysfunction in molar pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 184.e1-184.e5.	2.4	44
191	Early-pregnancy soluble Fas levels in idiopathic small-for-gestational-age pregnancies. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 299.e1-299.e7.	2.4	5
192	Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease. <i>PLoS ONE</i> , 2010, 5, e9246.	2.3	44
193	Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor Signaling Inhibitors. <i>Hypertension</i> , 2010, 56, 1131-1136.	6.6	112
194	First Trimester Vitamin D, Vitamin D Binding Protein, and Subsequent Preeclampsia. <i>Hypertension</i> , 2010, 56, 758-763.	6.6	157
195	Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy. <i>Hypertension</i> , 2010, 55, 1239-1245.	6.6	109
196	Placental Vasculature in Health and Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 309-320.	2.5	50
197	Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. <i>Seminars in Nephrology</i> , 2010, 30, 591-601.	2.3	199
198	Pathogenesis of Preeclampsia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2010, 5, 173-192.	30.6	600

#	ARTICLE	IF	CITATIONS
199	Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With Placentalschemia-Induced Hypertension. <i>Hypertension</i> , 2010, 55, 380-385.	6.6	160
200	First-Trimester Follistatin-Like-3 Levels in Pregnancies Complicated by Subsequent Gestational Diabetes Mellitus. <i>Diabetes Care</i> , 2010, 33, 664-669.	6.2	38
201	Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 73-78.	1.2	7
202	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 366-370.	1.7	54
203	Angiotensin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium. <i>Molecular and Cellular Biology</i> , 2009, 29, 2011-2022.	2.5	354
204	Franklin H. Epstein—Researcher, Teacher, Clinician, and Humanist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1285-1289.	4.2	2
205	Circulating angiogenic factors in gestational proteinuria without hypertension. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 392.e1-392.e10.	2.4	43
206	Reactions of Peroxynitrite with Uric Acid: Formation of Reactive Intermediates, Alkylated Products and Triuret, and In Vivo Production of Triuret Under Conditions of Oxidative Stress. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 118-149.	1.6	87
207	Klotho Variants and Chronic Hemodialysis Mortality. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1847-1855.	4.9	56
208	Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis. <i>Physiology</i> , 2009, 24, 147-158.	5.0	407
209	Hemodynamically-Directed Atenolol Therapy is Associated with a Blunted Rise in Maternal sFLT-1 Levels During Pregnancy. <i>Hypertension in Pregnancy</i> , 2009, 28, 42-55.	1.2	16
210	Risk for developing gestational diabetes in women with twin pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2009, 22, 293-299.	1.7	142
211	Advances in the understanding of eclampsia. <i>Current Hypertension Reports</i> , 2008, 10, 305-312.	4.8	57
212	Circulating soluble endoglin and placental abruption. <i>Prenatal Diagnosis</i> , 2008, 28, 852-858.	2.3	45
213	Targeting tumor vascular endothelium: an emerging concept for cancer therapy. <i>Drug Development Research</i> , 2008, 69, 340-351.	3.4	1
214	Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 428.e1-428.e6.	2.4	208
215	Use of Circulating Antiangiogenic Factors to Differentiate Other Hypertensive Disorders From Preeclampsia in a Pregnant Woman on Dialysis. <i>American Journal of Kidney Diseases</i> , 2008, 51, 1029-1032.	1.4	26
216	Molecular mechanisms of preeclampsia. <i>Microvascular Research</i> , 2008, 75, 1-8.	2.5	264

#	ARTICLE	IF	CITATIONS
217	Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. <i>Biochemical and Biophysical Research Communications</i> , 2008, 371, 475-479.	2.1	29
218	Preeclampsia and Angiogenic Imbalance. <i>Annual Review of Medicine</i> , 2008, 59, 61-78.	18.7	302
219	A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin) Tj ETQq1 1 0.784314 rgBT /Overl destined to develop preeclampsia and deliver a small for gestational age neonate. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 9-23.	1.7	621
220	Elevated levels of placental growth factor represent an adaptive host response in sepsis. <i>Journal of Experimental Medicine</i> , 2008, 205, 2623-2631.	9.2	41
221	VEGF and TGF- β 2 are required for the maintenance of the choroid plexus and ependyma. <i>Journal of Experimental Medicine</i> , 2008, 205, 491-501.	9.2	186
222	Vascular endothelial growth factor decreases blood pressure in hypertensive pregnant rats. <i>FASEB Journal</i> , 2008, 22, .	0.6	0
223	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16810-16815.	7.5	312
224	Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia. <i>Hypertension</i> , 2007, 50, 137-142.	6.6	280
225	Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia. <i>Hypertension</i> , 2007, 50, 686-692.	6.6	241
226	Pathophysiology of the Clinical Manifestations of Preeclampsia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 543-549.	4.2	219
227	Endothelial Dysfunction. <i>Hypertension</i> , 2007, 49, 90-95.	6.6	256
228	Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic markers in preeclampsia and preexisting diabetes. <i>Diabetes Care</i> , 2007, 30, 375-377.	6.2	26
229	Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Circulating Antiangiogenic Factors. <i>Obstetrics and Gynecology</i> , 2007, 109, 549-552.	1.9	59
230	Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. <i>Obstetrical and Gynecological Survey</i> , 2007, 62, 82-83.	0.5	20
231	Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. <i>FASEB Journal</i> , 2007, 21, 3171-3183.	0.6	104
232	Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. <i>Journal of Reproductive Immunology</i> , 2007, 76, 23-29.	1.2	60
233	Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 176.e1-176.e6.	2.4	73
234	Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 28.e1-28.e6.	2.4	108

#	ARTICLE	IF	CITATIONS
235	Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. <i>New England Journal of Medicine</i> , 2006, 355, 992-1005.	34.6	1,767
236	Late Postpartum Eclampsia: Examples and Review. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 471-480.	0.5	42
237	Circulating Angiogenic Factors and Placental Abruption. <i>Obstetrics and Gynecology</i> , 2006, 108, 338-344.	1.9	98
238	Soluble endoglin contributes to the pathogenesis of preeclampsia. <i>Nature Medicine</i> , 2006, 12, 642-649.	33.0	1,747
239	Circulating angiogenic proteins in trisomy 13. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 239-245.	2.4	69
240	Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1034-1041.	2.4	109
241	Protease Activity of Urokinase and Tumor Progression in a Syngeneic Mammary Cancer Model. <i>Journal of the National Cancer Institute</i> , 2006, 98, 756-764.	4.6	14
242	Lipocalin 2 Antagonizes the Proangiogenic Action of Ras in Transformed Cells. <i>Molecular Cancer Research</i> , 2006, 4, 821-829.	3.1	30
243	Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. <i>Journal of Experimental Medicine</i> , 2006, 203, 1447-1458.	9.2	260
244	Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans. <i>PLoS Medicine</i> , 2006, 3, e46.	8.1	477
245	Circulating Angiogenic Factors in Preeclampsia. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 372-386.	1.2	131
246	Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 16-22.	2.4	116
247	Preeclampsia: A renal perspective. <i>Kidney International</i> , 2005, 67, 2101-2113.	5.3	265
248	Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. <i>Oncogene</i> , 2005, 24, 7850-7858.	6.5	51
249	Extra-placental Expression of Vascular Endothelial Growth Factor Receptor-1, (Flt-1) and Soluble Flt-1 (sFlt-1), by Peripheral Blood Mononuclear Cells (PBMCs) in Normotensive and Preeclamptic Pregnant Women. <i>Placenta</i> , 2005, 26, 563-573.	1.1	178
250	Lipocalin 2 Diminishes Invasiveness and Metastasis of Ras-transformed Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 13641-13647.	2.2	110
251	Urinary Placental Growth Factor and Risk of Preeclampsia. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 77.	16.6	314
252	Vascular Endothelial Growth Factor Induces Branching Morphogenesis/Tubulogenesis in Renal Epithelial Cells in a Neuropilin-Dependent Fashion. <i>Molecular and Cellular Biology</i> , 2005, 25, 7441-7448.	2.5	56

#	ARTICLE	IF	CITATIONS
253	Uric acid and preeclampsia. <i>Seminars in Nephrology</i> , 2005, 25, 56-60.	2.3	80
254	Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia. <i>Hypertension</i> , 2005, 46, 1077-1085.	6.6	356
255	Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia. <i>Pediatric Research</i> , 2005, 57, 1R-7R.	2.3	227
256	Angiogenic Factors in the Pathogenesis of Preeclampsia. <i>Current Topics in Developmental Biology</i> , 2005, , 297-312.	6.6	67
257	Hypoxia and sFlt-1 in Preeclampsia: The "Chicken-and-Egg" Question. <i>Endocrinology</i> , 2004, 145, 4835-4837.	2.5	184
258	Insulin Resistance and Alterations in Angiogenesis. <i>Hypertension</i> , 2004, 43, 988-992.	6.6	96
259	Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6239-6243.	4.1	201
260	Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. <i>Seminars in Nephrology</i> , 2004, 24, 548-556.	2.3	95
261	Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. <i>Kidney International</i> , 2004, 66, 281-287.	5.3	206
262	Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. <i>Kidney International</i> , 2004, 66, 1471-1478.	5.3	28
263	First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 770-775.	4.1	406
264	Circulating Angiogenic Factors and the Risk of Preeclampsia. <i>New England Journal of Medicine</i> , 2004, 350, 672-683.	34.6	3,445
265	Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. <i>Seminars in Nephrology</i> , 2004, 24, 548-556.	2.3	46
266	Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. <i>Journal of Clinical Investigation</i> , 2003, 111, 649-658.	10.6	3,628
267	Endostatin is a potential inhibitor of Wnt signaling. <i>Journal of Cell Biology</i> , 2002, 158, 529-539.	5.4	143
268	Renal cancer: molecular mechanisms and newer therapeutic options. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 37-42.	2.2	83
269	Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1. <i>Journal of Biological Chemistry</i> , 2002, 277, 16464-16469.	2.2	201
270	Cellular Actions and Signaling by Endostatin. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2002, 12, 175-192.	1.2	17

#	ARTICLE	IF	CITATIONS
271	Cellular Actions and Signaling by Endostatin. Critical Reviews in Eukaryotic Gene Expression, 2002, 12, 17.	1.2	0
272	VHL tumor suppressor regulates Cl ⁻ /HCO ₃ ⁻ exchange and Na ⁺ /H ⁺ exchange activities in renal carcinoma cells. Physiological Genomics, 2001, 5, 119-128.	2.5	41
273	Title is missing!. , 0, .		1
274	Hypoxia-inducible factor 1 signaling drives placental aging and can provoke preterm labor. ELife, 0, 12, .	1.6	24
275	Hypoxia-inducible factor 1 signaling drives placental aging and can provoke preterm labor. ELife, 0, 12, .	1.6	0
276	Antiferroptotic Drugs Reduce sFlt-1 Release and Placenta Damage in Preeclampsia. Hypertension, 0, 82, 1705-1718.	6.6	1
277	Butyrophilin 2A2 promotes T cell immunoregulation via CD45 phosphatase activation and protects against murine autoimmune glomerulonephritis and pregnancy loss. Nature Communications, 0, 17, .	13.7	0